close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vistagen Therapeutics, Inc. - Common Stock (NQ:VTGN)

0.7700 -3.5900 (-82.34%)
Streaming Delayed Price Updated: 12:01 PM EST, Dec 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vistagen Therapeutics, Inc. - Common Stock

< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
News headline image
Vistagen Announces Completion of Last Patient, Last Visit in Phase 2 Clinical Trial of PH94B for the Treatment of Adjustment Disorder with Anxiety
From Vistagen
Via Business Wire
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Takes Key Steps to Protect, Enhance IP Program
Via Investor Brand Network
Topics Intellectual Property
News headline image
Vistagen Advances Intellectual Property Program to Expand Patent Protection for PH94B to Include Treatment of Adjustment Disorder
From Vistagen
Via Business Wire
News headline image
VistaGen Therapeutics Earnings Perspective: Return On Capital Employed ↗
 
Via Benzinga
News headline image
Why Cal-Maine Foods Shares Are Trading Lower; Here Are 24 Stocks Moving Premarket ↗
Gainers Quotient Limited (NASDAQ: QTNT) shares rose 125% to $0.54 in pre-market trading after dropping around 38% on Wednesday. Quotient recently announced the intent to voluntary delist from the... 
Via Benzinga
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Plans to Acquire Pherin Pharmaceuticals Inc.
Via Investor Brand Network
News headline image
Vistagen Strengthens Its Neurology Focused Pipeline With Pherin Pharma Acquisition ↗
 
Via Benzinga
News headline image
Vistagen to Acquire Pherin Pharmaceuticals
From Vistagen
Via Business Wire
News headline image
Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session ↗
Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
KCSA Mental Health Virtual Investor Conference: Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
KCSA Mental Health Virtual Investor Conference Agenda Announced for December 15th
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces FDA Fast Track Designation for Development of Proprietary MDD Treatment
Via Investor Brand Network
News headline image
Why Summit Therapeutics Shares Are Trading Higher By Over 82%? Here Are 53 Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers Summit Therapeutics Inc. (NASDAQ: SMMT) shares surged 82.2% to $1.4299 after the company announced a definitive agreement of its partnership with Akeso to in-license its breakthrough bispecific... 
Via Benzinga
News headline image
Vistagen Receives FDA Fast Track Designation for Development of PH10 to Treat Major Depressive Disorder
From Vistagen
Via Business Wire
News headline image
Vistagen Receives FDA “Study May Proceed” Letter Under its Investigational New Drug Application for PH10 to Treat Major Depressive Disorder
From Vistagen
Via Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Publishes Positive Preclinical Findings Related to AV-101
Via Investor Brand Network
News headline image
Vistagen Announces Publication in Cells Demonstrating AV-101’s Potential for Treating Levodopa-Induced Dyskinesia in Patients with Parkinson's Disease
From Vistagen
Via Business Wire
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Releases Q2 2023 Financial Report, Corporate Update
Via Investor Brand Network
News headline image
Vistagen Reports Second Quarter Financial Results and Provides Corporate Update
From Vistagen
Via Business Wire
News headline image
Earnings Scheduled For November 10, 2022 ↗
Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report earnings for its third quarter. 
Via Benzinga
News headline image
Earnings Outlook For VistaGen Therapeutics ↗
VistaGen Therapeutics (NASDAQ:VTGN) is set to give its latest quarterly earnings report on Thursday, 2022-11-10. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Host Q2 2023 Financial Results Call, Webcast
Via Investor Brand Network
News headline image
Vistagen to Report Fiscal Year 2023 Second Quarter Financial Results on November 10, 2022
From Vistagen
Via Business Wire
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Participate at Stifel 2022 Healthcare Conference
Via Investor Brand Network
< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today